Lotte Biologics to Present Research Results on ADC Platform 'SoluFlex Link' at AACR

by Kwak Minjae

Published 15 Apr.2026 09:48(KST)

Lotte Biologics announced on April 15 that it will present research results related to its antibody-drug conjugate (ADC) platform, "SoluFlex Link," at the American Association for Cancer Research (AACR 2026), which will be held in San Diego, United States, from April 17 to April 22.

Lotte Biologics Songdo Bio Campus bird's-eye view. Lotte Biologics

AACR is considered one of the world’s top three cancer societies, alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). It is an academic conference where experts and industry professionals from around the globe gather to discuss cancer treatment and new drug development.

Lotte Biologics will unveil the results of the structural stability assessment of an ADC developed in collaboration with Kanaph Therapeutics and utilizing SoluFlex Link technology.

According to the company, in the analysis of aggregate changes over time, the control group without the SoluFlex linker showed increased aggregation as time passed, whereas the group with the SoluFlex linker exhibited significantly suppressed aggregation and maintained high stability. The company explained that using SoluFlex Link enables stable quality management during distribution and storage processes as well.

In addition, the company plans to announce that, in cell experiments targeting various markers such as epidermal growth factor receptor (EGFR) and trophoblast cell surface antigen-2 (TROP-2), the SoluFlex Link group demonstrated superior anticancer effects even at lower concentrations compared to the non-linker group, and also showed excellent efficacy in triple-negative breast cancer cells.

The company stated that, in animal studies, the ADCs using SoluFlex Link demonstrated improved in vivo pharmacokinetics (PK) based on high stability. Lotte Biologics explained that these results prove the potential of SoluFlex Link as a platform technology that is not limited to specific antibodies and can enhance both anticancer efficacy and pharmacokinetic properties.

A representative from Lotte Biologics commented, "SoluFlex Link is a differentiated platform that overcomes the limitations of existing technologies," adding, "We will provide solutions so that our partners or clients can successfully develop next-generation ADCs."